Chimeric Therapeutics Limited (CHMMF)
OTCMKTS · Delayed Price · Currency is USD
0.0010
-0.0290 (-96.67%)
At close: Sep 6, 2024
Chimeric Therapeutics Revenue
In the fiscal year ending June 30, 2025, Chimeric Therapeutics had annual revenue of 12.68M AUD with 70.09% growth. Chimeric Therapeutics had revenue of 7.13M in the half year ending June 30, 2025, with 376.67% growth.
Revenue
12.68M AUD
Revenue Growth
+70.09%
P/S Ratio
0.77
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.41M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.68M | 5.23M | 70.09% |
| Jun 30, 2024 | 7.46M | 2.95M | 65.52% |
| Jun 30, 2023 | 4.51M | 1.89M | 72.16% |
| Jun 30, 2022 | 2.62M | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Longduoduo Company | 4.99M |